Summary
Human recombinant tumor necrosis factor-α (rTNF-α) was administered to normal Fischer 344 rats by stereotaxic intracerebral (IC) injection. Animals receiving a single injection of either 6 x 104 U rTNF-α or an equivalent volume of excipient (vehicle) in their right parietal lobe. In order to demonstrate any effects rTNF-α might have on the blood-brain barrier (BBB), two studies were conducted, one employing exogenous horseradish peroxidase (HRP, 44 kD) as a tracer of BBB permeability and the other using endogenous IgG (150 kD). Rats given rTNF-α showed transitory BBB permeability to HRP by 24 hours post-injection; this BBB compromise was determined to be no longer than 60 hours. In the other study, IgG was seen to cross the BBB by 48 hours post-rTNF-α injection. Alternatively, rats injected IC with excipient showed only limited BBB opening as a result of injection-induced trauma. We conclude that human rTNF-α, injected IC into normal rats triggers a temporary breakdown in BBB integrity which begins sometimes between 12 and 24 hours post-injection, is large enough to permit macromolecules of at least 150 kD to pass, and resolves by 72 hours post-injection.
Similar content being viewed by others
References
Gordon CR, Merchant RE, Marmarou A, Rice CD, Marsh JT, Young HF: Effect of murine recombinant interleukin-l on brain edema in the rat. Acta Neurochir Suppl 51: 268–270, 1990
Kido G, Wright JL, Merchant RE: Acute effects of human recombinant tumor necrosis factor-a on the cerebral vasculature of the rat in both normal brain and in an experimental glioma model. J Neuro-Oncol 10: 95–109, 1991
Rice CD, Merchant RE: Systemic treatment with murine recombinant interleukin-lβ inhibits the growth and progression of malignant glioma in the rat. J Neuro-Oncol 13: 43–55, 1992
Watts RG, Wright JL, Atkinson LL, Merchant RE: Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin 2. Neurosurgery 25: 202–208, 1989
Watts RG, Merchant RE: Cerebrovascular effects and tumor kinetics after a single intratumoral injection of human recombinant interleukin-2 alone or in combination with intravenous chemotherapy in a rat model of glioma. Neurosurgery 31: 89–99, 1992
Wright JL, Merchant RE: Histopathological effects of intracerebral injections of human recombinant tumor necrosis factor-a in the rat. Acta Neuropathol 85: 93–100, 1992
Ellison MD, Povlishock JT, Merchant RE: Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 47: 5765–5770, 1987
Ellison MD, Krieg RJ, Merchant RE: Cerebral vasomotor responses after recombinant interleukin-2 infusion. Cancer Res 50: 4377–4381, 1990
Merchant RE, Grant AJ, Merchant LH, Young HF: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer (LAK) cells and recombinant interleukin-2. Cancer 62: 665–671, 1988
Merchant RE, Merchant LH, Cook SH, McVicar DW, Young HF: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23: 725–732, 1988
Clark I, Ilschner S, MacMicking J, Cowden W: TNF andPlasmodium berghei ANKA-induced cerebral malaria. Immuno Lett 25: 195–198, 1990
Braquet P, Hosford D, Braquet M, Bourgain R, Bussolino F: Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol 88: 88–100, 1989
Movat HZ: Tumor necrosis factor and interleukin-1: role in acute inflammation and microvascular injury. J Lab Clin Med 110: 668–681, 1987
Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A, Tuomanen E: The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med 171: 439–448, 1990
Quagliarello V, Wispelwey B, Long W, Scheid W: Recombinant interleukin-l induces meningitis and blood-brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. J Clin Invest 87: 1360–1366, 1991
Sharief M, Ciardi M, Thompson E: Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-l beta. J Infect Dis 166: 350–358, 1992
Mullin JM, Snock KV: Effects of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res 50: 2172–2176, 1990
Saegusa Y, Ziff M, Weikovich L, Cavender D: Effect of inflammatory cytokines on human endothelial cell proliferation. J Cell Physiol 142: 488–495, 1990
Yoshida S, Minakawa T, Takai N, Tanaka R: Effects of cytokines on cultured microvascular endothelial cells derived from gerbil brain. Neurosurgery 25: 373–377, 1989
Andersson P-B, Perry V, Gordon S: Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. J Exp Med 176: 255–259, 1992
Kuroiwa T, Cahn R, Juhler M, Goping G, Campbell G, Klatzo I: Role of extracellular proteins in the dynamics of vasogenic brain edema. Acta Neuropathol 66: 3–11, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wright, J.L., Merchant, R.E. Blood-brain barrier changes following intracerebral injection of human recombinant tumor necrosis factor-α in the rat. J Neuro-Oncol 20, 17–25 (1994). https://doi.org/10.1007/BF01057957
Issue Date:
DOI: https://doi.org/10.1007/BF01057957